Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms

a study on Appendiceal Mucinous Neoplasm Pseudomyxoma Peritonei

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Irvine
Dates
study started
study ends around
Principal Investigator
by Oliver Eng (uci)

Description

Summary

This is a pilot, open-label clinical trial determining the feasibility of metformin therapy in subjects with pseudomyxoma peritoneal (PMP) secondary to appendiceal mucinous neoplasms (AMNs).

Official Title

Use of Metformin in Patients With Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms

Details

This is a single-arm, prospective pilot/feasibility study. Treatment will continue for the duration of the study (18 months) or intolerance to treatment. The primary endpoint will be feasibility of metformin therapy in patients with PMP secondary to AMNs.

Keywords

Appendiceal Mucinous Neoplasm, Pseudomyxoma Peritonei, Pseudomyxoma Peritoneal, PMP, AMNs, Metformin

Eligibility

You can join if…

Open to people ages 18 years and up

(complete details available in protocol):

  • Patients with clinical diagnosis of PMP secondary to presumed AMNs with recurrent/refractory disease s/p CRS/HIPEC, unresectable disease, or without planned CRS/HIPEC
  • Age ≥18 years
  • ECOG performance status ≤2

You CAN'T join if...

(complete details available in protocol):

  • Patients with a clinical diagnosis of PMP secondary to presumed AMNs with resectable disease who are planned to undergo CRS/HIPEC
  • Patients currently taking metformin for another medical indication
  • Patients with a prior adverse event to administration of metformin

Location

  • Chao Family Comprehensive Cancer Center, University of California, Irvine accepting new patients
    Orange California 92868 United States

Lead Scientist at University of California Health

  • Oliver Eng (uci)
    Associate Clinical Professor, Surgery, School of Medicine. Authored (or co-authored) 150 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Irvine
ID
NCT07693452
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 15 study participants
Last Updated
Contact us about this trial